A5401 COVID Supplement
- Funded by National Institutes of Health (NIH)
- Total publications:0 publications
Grant number: unknown
Grant search
Key facts
Disease
COVID-19Start & end year
20202020Known Financial Commitments (USD)
$3,770,048Funder
National Institutes of Health (NIH)Principal Investigator
PendingResearch Location
United States of AmericaLead Research Institution
University of California-Los AngelesResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementation
Research Subcategory
Prophylactic use of treatments
Special Interest Tags
N/A
Study Type
Unspecified
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
ABSTRACTThe AIDS Clinical Trials Group (ACTG) has been selected to lead a Master Adaptive protocol under theAccelerating COVID-19 Therapeutic Interventions and Vaccine (ACTIV) Operation Warp Speed. This trial(ACTG 5401 or ACTIV-2) will evaluate multiple monoclonal antibodies and other small molecules for outpatientCOVID treatment. The Laboratory Center will expand its efforts to include support for COVID-19 clinical trials.